Evaluating drugs after their approval for clinical use

Raymond L. Woosley, David A. Flockhart, Wayne A. Ray, Marie R. Griffin, Jerry Avorn

Research output: Contribution to journalLetter

2 Scopus citations

Abstract

To the Editor: Ray et al. (Dec. 30 issue)1 are to be complimented on their arguments in favor of changing the way we evaluate drugs after they have been approved for clinical use. As clinical pharmacologists, we strongly endorse their proposals for more research in this area and for a national center for the evaluation of new drugs. Independently, we arrived at similar conclusions and have proposed the creation of centers for education and research in therapeutics2. The concept of an independently funded center that could conduct research on drugs is not new. An important opportunity was lost in.

Original languageEnglish (US)
Pages (from-to)1394-1395
Number of pages2
JournalNew England Journal of Medicine
Volume330
Issue number19
DOIs
StatePublished - May 12 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluating drugs after their approval for clinical use'. Together they form a unique fingerprint.

  • Cite this

    Woosley, R. L., Flockhart, D. A., Ray, W. A., Griffin, M. R., & Avorn, J. (1994). Evaluating drugs after their approval for clinical use. New England Journal of Medicine, 330(19), 1394-1395. https://doi.org/10.1056/NEJM199405123301920